Cryptococcal capsular glucuronoxylomannan reduces ischaemia-related neutrophil influx

European Journal of Clinical Investigation

Volumn 34, Issue 9, 2004, Pages 631-640

  Ellerbroek, Pauline Marit ^a,d   Schoemaker, R G ^b   Van Veghel, R ^c   Hoepelman, A I M ^a   Coenjaerts, F E J ^a,d  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cryptococcus; Glucuronoxylomannan; Inflammation; Ischaemia; Myocardium; Neutrophils

Indexed keywords

CAPSULAR POLYSACCHARIDE; COMPLEMENT COMPONENT C5A; GLUCURONOXYLOMANNAN; MYELOPEROXIDASE; POLYSACCHARIDE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CHEMOTAXIS; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CORONARY ARTERY LIGATION; CRYPTOCOCCUS NEOFORMANS; ENZYME ACTIVITY; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; INFLAMMATION; INFLAMMATORY CELL; ISCHEMIA; LEUKOCYTE MIGRATION; MALE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY;

ANIMALS; COMPLEMENT C5; CORONARY VESSELS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; LIGATION; MALE; MYOCARDIAL ISCHEMIA; NEUTROPHILS; POLYSACCHARIDES; RATS; RATS, WISTAR;

EID: 4944257213     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2004.01393.x     Document Type: Article

References (68)

1. Gutierrez F, Fu YS, Lune H. Cryptococcosis histologically resembling histoplasmosis. A light and electron microscopical study. Arch Pathol 1975;99:347-52.
2. Chaka W, Heyderman R, Gangaidzo I, Robertson V, Mason P, Hoepelman AI et al. Cytokine profiles in cerebrospinal fluid of human immunodeficiency virus-infected patients with cryptococcal meningitis: no leukocytosis despite high interleukin-8 levels. University of Zimbabwe Meningitis Group. J Infect Dis 1997;176:1633-6.
3. Eng RH, Bishburg E, Smith SM, Kapila R. Cryptococcal infections in patients with acquired immune deficiency syndrome. Am J Med 1986;81:19-23.
4. Metta HA, Corti ME, Negroni R, Helou S, Arechavala A, Soto I et al. Disseminated cryptococcosis in patients with AIDS. Clinical, microbiological, and immunological analysis of 51 patients. Rev Argent Microbiol 2002;34:117-23.
5. Dong ZM, Murphy JW. Intravascular cryptococcal culture filtrate (CneF) and its major component, glucuronoxylomannan, are potent inhibitors of leukocyte accumulation. Infect Immun 1995;63:770-8.
6. Lipovsky MM, Gekker G, Hu S, Ehrlich LC, Hoepelman AI, Peterson PK. Cryptococcal glucuronoxylomannan induces interleukin (IL)-8 production by human microglia but inhibits neutrophil migration toward IL-8. J Infect Dis 1998;177:260-3.
7. Coenjaerts FE, Walenkamp AM, Mwinzi PN, Scharringa J, Dekker HA, van Strijp JA et al. Potent inhibition of neutrophil migration by cryptococcal mannoprotein-4-induced desensinzation. J Immunol 2001;167:3988-95.
8. Retini C, Vecchiarelli A, Monari C, Tascini C, Bistoni F, Kozel TR. Capsular polysaccharide of Cryptococcus neoformans induces proinflammatory cytokine release by human neutrophils. Infect Immun 1996;64:2897-903.
9. Dong ZM, Murphy JW. Effects of the two varieties of Cryptococcus neoformans cells and culture nitrate antigens on neutrophil locomotion. Infect Immun 1995;63:2632-44.
10. Dong ZM, Murphy JW. Mobility of human neutrophils in response to Cryptococcus neoformans cells, culture nitrate antigen, and individual components of the antigen. Infect Immun 1993;61:5067-77.
11. Monari C, Kozel TR, Bistoni F, Vecchiarelli A. Modulation of C5aR Expression on Human Neutrophils by Encapsulated and Acapsular Cryptococcus neoformans. Infect Immun 2002;70:3363-70.
12. Blackstock R, Murphy JW. Secretion of the C3 component of complement by peritoneal cells cultured with encapsulated Cryptococcus neoformans. Infect Immun 1997;65:4114-21.
13. Kozel TR, Wilson MA, Murphy JW. Early events in initiation of alternative complement pathway activation by the capsule of Cryptococcus neoformans. Infect Immun 1991;59:3101-10.
14. Dong ZM, Murphy JW. Cryptococcal polysaccharides induce 1-selectin shedding and tumor necrosis factor receptor loss from the surface of human neutrophils. J Clin Invest 1996;97:689-98.
15. Dong ZM, Jackson L, Murphy JW. Mechanisms for induction of 1-selectin loss from T lymphocytes by a cryptococcal polysaccharide, glucuronoxylomannan. Infect Immun 1999;67:220-9.
16. Dong ZM, Murphy JW. Cryptococcal polysaccharides bind to CD18 on human neutrophils. Infect Immun 1997;65:557-63.
17. Ellerbroek PM, Ulfman LH, Hoepelman IM, Coenjaerts FEJ. Cryptococcal glucuronoxylomannan interferes with neutrophil rolling on the endothelium. Cell Microbial 2004;6:581-92.
18. Ellerbroek PM, Hoepelman AI, Wolbers F, Zwaginga JJ, Coenjaerts FE. Cryptococcal glucuronoxylomannan inhibits adhesion of neutrophils to stimulated endothelium in vitro by affecting both neutrophils and endothelial cells. Infect Immun 2002;70:4762-71.
19. Lipovsky MM, van Elden LJ, Walenkamp AM, Dankert J, Hoepelman AI. Does the capsule component of the Cryptococcus neoformans glucuronoxylomannan impair transendothelial migration of leukocytes in patients with cryptococcal meningitis? J Infect Dis 1998;178:1231-2.
20. Lipovsky MM, Tsenova L, Coenjaerts FE, Kaplan G, Cherniak R, Hoepelman AI. Cryptococcal glucuronoxylomannan delays translocation of leukocytes across the blood-brain barrier in an animal model of acute bacterial meningitis. J Neuroimmunol 2000;111:10-4.
21. Mirshafiey A, Chitsaz M, Attar M, Mehrabian F, Razavi AR. Culture filtrate of Cryptococcus neoformans var. gattii (CneF) as a novel anti-inflammatory compound in the treatment of experimental septic arthritis. Scand J Immunol 2000;52:278-84.
22. Mirshafiey A, Razavi A, Mehrabian F, Moghaddam MR, Hadjavi M. Treatment of experimental nephrosis by culture nitrate of Cryptococcus neoformans var. gattii (CneF). Immunopharmacol Immunotoxicol 2002;24:349-64.
23. Mirshafiey A, Mehrabian F, Razavi A, Shidfar MR, Namaki S. Novel therapeutic approach by culture filtrate of Cryptococcus neoformans var. gattii (CneF) in experimental immune complex glomerulonephritis. Generalpharmacol 2000;34:311-9.
24. Maxwell SR, Lip GY. Reperfusion injury: a review of the pathophysiology, clinical manifestations and therapeutic options. Int J Cardiol 1997;58:95-117.
25. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002;53:31-47.
26. Hansen PR. Role of neutrophils in myocardial ischemia and reperfusion. Circulation 1995;91:1872-85.
27. Smith EF III, Egan JW, Bugelski PJ, Hillegass LM, Hill DE, Griswold DE. Temporal relation between neutrophil accumulation and myocardial reperfusion injury. Am J Physiol 1988;255:H1060-8.
28. Dreyer WJ, Michael LH, West MS, Smith CW, Rothlein R, Rossen RD et al. Neutrophil accumulation in ischemic canine myocardium. Insights into time course, distribution, and mechanism of localization during early reperfusion. Circulation 1991;84:400-11.
29. Romson JL, Hook BG, Kunkel SL, Abrams GD, Schork MA, Lucchesi BR. Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog. Circulation 1983;67:1016-23.
30. Engler RL, Dahlgren MD, Morris DD, Peterson MA, Schmid-Schonbein GW. Role of leukocytes in response to acute myocardial ischemia and reflow in dogs. Am J Physiol 1986;251:H314-23.
31. Lefer DJ, Flynn DM, Phillips ML, Ratcliffe M, Buda AJ. A novel sialyl LewisX analog attenuates neutrophil accumulation and myocardial necrosis after ischemia and reperfusion. Circulation 1994;90:2390-401.
32. Kilgore KS, Park JL, Chi L, Musser JH, Date VV, Abbas S et al. Reduction of myocardial infarct size in the rabbit by a carbohydrate analog of Sialyl Lewis (x). J Cardiovasc Pharmacol Ther 1996;1:49-56.
33. Hoffineyer MR, Scalia R, Ross CR, Jones SP, Lefer DJ. PR-39, a potent neutrophil inhibitor, attenuates myocardial ischemia-reperfusion injury in mice. Am J Physiol Heart Circ Physiol 2000;279:H2824-8.
34. Kohtani T, Abe Y, Sato M, Miyauchi K, Kawachi K. Protective effects of anti-neutrophil antibody against myocardial ischemia/reperfusion injury in rats. Eur Surg Res 2002;34:313-20.
35. Cherniak R, Morris LC, Anderson BC, Meyer SA. Facilitated isolation, purification, and analysis of glucuronoxylomannan of Cryptococcus neoformans. Infect Immun 1991;59:59-64.
36. Fishbein MC, Maclean D, Maroko PR. Experimental myocardial infarction in the rat: qualitative and quantitative changes during pathologic evolution. Am J Pathol 1978;90:57-70.
37. Schoemaker RG, Debets JJ, Struyker-Boudier HA, Smits JF. Delayed but not immediate captopril therapy improves cardiac function in conscious rats, following myocardial infarction. J Mol Cell Cardiol 1991;23:187-97.
38. Kalkman EA, van Suylen RJ, van Dijk JP, Saxena PR, Schoemaker RG. Chronic aspirin treatment affects collagen deposition in non-infarcted myocardium during remodeling after coronary artery ligation in the rat. J Mol Cell Cardiol 1995;27:2483-94.
39. Xia Y, Zweier JL. Measurement of myeloperoxidase in leukocyte-containing tissues. Anal Biochem 1997;245:93-6.
40. Bradley PP, Priebat DA, Christensen RD, Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 1982;78:206-9.
41. Tiefenbacher CP, Kapitza J, Dietz V, Lee CH, Niroomand F. Reduction of myocardial infarct size by fluvastatin. Am J Physiol Heart Circ Physiol 2003;285:H59-64.
42. Griswold DE, Hillegass LM, Hill DE, Egan JW, Smith EF III Method for quantification of myocardial infarction and inflammatory cell infiltration in rat cardiac tissue. J Pharmacol Meth 1988;20:225-35.
43. Schoemaker RG, van Heijningen CL. Bradykinin mediates cardiac preconditioning at a distance. Am J Physiol Heart Circ Physiol 2000;278:H1571-6.
44. Pillener L, Blum L, Lepow IH, Ross OA, Todd EW, Wardlaw AC. The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science 1954;120:279-85.
45. Fearon DT, Austen KF. Activation of the alternative complement pathway due to resistance of zymosan-bound. Proc Natl Acad Sci USA 1977;74:1683-7.
46. Kew RR, Peng T, DiMartino SJ, Madhavan D, Weinman SJ, Prossnitz ER et al. Undifferentiated U937 cells transfected with chemoattractant receptors: a model system to investigate chemotactic mechanisms and receptor structure/function relationships. J Leukoc Biol 1997;61:329-37.
47. Burchiel SW, Edwards BS, Kuckuck FW, Lauer FT, Prossnitz ER, Ransom JT et al. Analysis of free intracellular calcium by flow cytometry: multiparameter and pharmacologic applications. Methods 2000;21:221-30.
48. Diamond RD, Erickson NF III Chemotaxis of human neutrophils and monocytes induced by Cryptococcus neoformans. Infect Immun 1982;38:380-2.
49. Klebanoff S. Myeloperoxidase: occurrence and biological function. In: Everse J, Everse KE, Grisham MB, eds. Peroxidases in Chemistry and Biology. Boca Raton: CRC Press;1991.p.1-35.
50. Eng R, Chmel H, Corrado M, Smith SM. The course of cryptococcal capsular polysaccharide antigenemia/human cryptococcal polysaccharide elimination kinetics. Infection 1983;11:132-6.
51. Goldman DL, Lee SC, Casadevall A. Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody. Infect Immun 1995;63:3448-53.
52. Lendvai N, Casadevall A, Liang Z, Goldman DL, Mukherjee J, Zuckier L. Effect of immune mechanisms on the pharmacokinetics and organ distribution of cryptococcal polysaccharide. J Infect Dis 1998;177:1647-59.
53. Grinsell M, Weinhold LC, Cutler JE, Han Y, Kozel TR. In vivo clearance of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans: a critical role for tissue macrophages. J Infect Dis 2001;184:479-87.
54. Delfino D, Cianci L, Migliardo M, Mancuso G, Cusumano V, Corradini C et al. Tumor necrosis factor-inducing activities of Cryptococcus neoformans components. Infect Immun 1996;64:5199-204.
55. Chaka W, Verheul AF, Vaishnav W, Cherniak R, Scharringa J, Verhoef J et al. Cryptococcus neoformans and cryptococcal glucuronoxylomannan, galactoxylomannan, and mannoprotein induce different levels of tumor necrosis factor alpha in human peripheral blood mononuclear cells. Infect Immun 1997;65:272-8.
56. Vecchiarelli A, Retini C, Casadevall A, Monari C, Pietrella D, Kozel TR. Involvement of C3a and C5a in interleukin-8 secretion by human polymorphonuclear cells in response to capsular material of Cryptococcus neoformans. Infect Immun 1998;66:4324-30.
57. Kozel TR. Activation of the complement system by the capsule of Cryptococcus neoformans. Curr Top Med 1993;5:1-26.
58. Truelsen K, Young T, Kozel TR. In vivo complement activation and binding of C3 to encapsulated Cryptococcus neoformans. Infect Immun 1992;60:3937-9.
59. Kozel TR, Levitz SM, Dromer F, Gates MA, Thorkildson P, Janbon G. Antigenic and biological characteristics of mutant strains of Cryptococcus neoformans lacking capsular O acetylation or xylosyl side chains. Infect Immun 2003;71:2868-75.
60. Laxalt KA, Kozel TR. Chemotaxigenesis and activation of the alternative complement pathway by encapsulated and non-encapsulated Cryptococcus neoformans. Infect Immun 1979;26:435-40.
61. Washburn RG, Bryant-Varela BJ, Julian NC, Bennett JE. Differences in Cryptococcus neoformans capsular polysaccharide structure influence assembly of alternative complement pathway C3 convertase on fungal surfaces. Mol Immunol 1991;28:465-70.
62. O'Neill PG, Charlat ML, Michael LH, Roberts R, Bolli R. Influence of neutrophil depletion on myocardial function and flow after reversible ischemia. Am J Physiol 1989;256:H341-51.
63. Tanaka M, Brooks SE, Richard VJ, FitzHarris GP, Stoler RC, Jennings RB et al. Effect of anti-CD18 antibody on myocardial neutrophil accumulation and infarct size after ischemia and reperfusion in dogs. Circulation 1993;87:526-35.
64. Birnbaum Y, Patterson M, Kloner RA. The effect of CY1503, a sialyl Lewisx analog blocker of the selectin adhesion molecules, on infarct size and 'no-reflow' in the rabbit model of acute myocardial infarction/reperfusion. J Mol Cell Cardiol 1997;29:2013-25.
65. Rusnak JM, Kopecky SL, Clements IP, Gibbons RJ, Holland AE, Peterman HS et al. An anti-CD11/CD18 monoclonal antibody in patients with acute myocardial infarction having percutaneous transluminal coronary angioplasty (the FESTIVAL study). Am J Cardiol 2001;88:482-7.
66. Baran KW, Nguyen M, McKendall GR, Lambrew CT, Dykstra G, Palmeri ST et al. Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study. Circulation 2001;104:2778-83.
67. Hoffman BF, Feinmark SJ, Guo SD. Electrophysiologic effects of interactions between activated canine neutrophils and cardiac myocytes. J Cardiovasc Electrophysiol 1997;8:679-87.
68. Dhein S, Schott M, Gottwald E, Muller A, Klaus W. The contribution of neutrophils to reperfusion arrhythmias and a possible role for antiadhesive pharmacological substances. Cardiovasc Res 1995;30:881-8.